HAVCR2 and neoplasm: Consistent with our epigenetic and transcriptional profiling data, CD8+ T cells from AC484-treated tumours had lower TIM-3 and TOX expression and an overall reduction in the frequency of TIM-3+ TOX+ cells compared with untreated mice and anti-PD-1-treated mice (Fig. 6c,d).